What You Should Know: - CancerIQ raises $5M in Series A funding led by HealthXVentures to accelerate the growth of its genetic cancer risk assessment platform to identify and manage patients at high risk of cancer. - CancerIQ’s technology enables hospitals to use genomics to personalize the prevention and early detection of cancer. - Two new hires recently joined CancerIQ’s newly formed Integrated Products team from Epic, with the goal of advancing CancerIQ’s integration with leading
Read More
Precision Oncology
MD Anderson, Philips Partner on Personalized Oncology Treatments, Clinical Trial Matching
What You Should Know: - Philips and MD Anderson collaborate to facilitate personalized oncology treatments and clinical trial matching based on genomic markers. - Philips connects oncologists and pathologists around the world to MD Anderson’s Precision Oncology Decision Support (PODS) system of actionable clinical information Philips and The University of Texas MD Anderson Cancer Center today announced a collaboration to provide oncologists with evidence-based therapy and clinical
Read More
Syapse Lands $30M to Accelerate Real-World Evidence in Oncology
What You Should Know: - Syapse raises $30M in new equity funding to enable healthcare providers to deliver the best care to every cancer patient through precision medicine. - Syapse partners with health systems, life sciences companies, and regulators to deliver clinical, programmatic, and research insights from the world’s largest network of health systems focused on precision medicine. Syapse, a San Francisco, CA-based provider of precision oncology solutions announced $30
Read More
Notable Launches Observational Clinical Trial for Patients with Blood Cancer
- Notable launches The ANSWer Study, it's new observational clinical trial for patients with blood cancer and is currently enrolling patients.- The primary assessment is to establish a tumor registry with annotated clinical outcomes.Notable, a San Francisco, CA-based company redefining cancer treatment with a clinically validated platform that rapidly advances drug development, is currently enrolling patients in its new observational clinical trial. The clinical trial will take place at
Read More
Top 60 Health IT/Digital Health Mergers & Acquisitions in 2019
- From Google's acquisition of Fitbit to Philips acquisition of Carestream Health's health IT business, here is a look at some of the biggest health IT/digital health mergers & acquisitions in 2019 by each quarter. Q1 M&A Activity Johnson & Johnson Acquires Auris Health for $3.4B to Expand Digital Surgery Portfolio Johnson & Johnson acquiresAuris Health, a developer of robotic technologies for $3.4 billion in cash. Auris Health is a privately-held developer of
Read More
HUG Becomes First European Hospital to Adopt IBM Watson for Genomics
- Swiss healthcare provider Hôpitaux Universitaires Genève (HUG) becomes the first European university hospital to use IBM Watson for Genomics. - IBM Watson for Genomics leverages AI to provide expertly validated, up-to-date, comprehensive content to enable clinical reporting & precision oncology programs. - The HUG is Switzerland's leading center for influenza and emerging viral infections, as well as for childhood liver disease and pediatric liver transplantation. Hôpitaux
Read More
FDA Cancer OCE, Syapse Partner on Regulatory Use of Real-World Evidence (RWE)
Syapse and the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) have signed a multi-year Research Collaboration Agreement (RCA) focused on the use of real-world evidence (RWE) to support regulatory decision-making. Syapse and the OCE will work with stakeholders across the FDA to address key regulatory questions about testing and treatment patterns, dosing and safety, and outcomes in oncology, with a focus on precision medicine.Methods to Derive RWE From Multiple
Read More
SHUH, Syapse to Build South Korea’s First Real-World Data Sharing Network for Precision Oncology Hospitals
SNUH and Syapse will collaboratively work towards building South Korea’s first real-world data-sharing network for leading precision oncology hospitals in the region. Syapse, a company accelerating precision medicine through insights derived from its global health system network, and Seoul National University Hospital (SNUH), a South Korea-based hospital, today announced that they have extended their partnership with a new multi-year agreement. As part of their partnership, SNUH and Syapse will
Read More
Pfizer, Syapse Partner on Oncology Precision Medicine Using Real-World Evidence (RWE)
Syapse, a San Francisco, CA-based precision medicine company, today announced that it has entered into a strategic collaboration with Pfizer to advance cancer outcomes research using real-world evidence (RWE) toward the ultimate goal of improving patient health. This collaboration will initially focus on the molecular testing and therapy choices on precision oncology journeys in the healthcare system setting.Syapse NetworkThe Syapse Network enables health systems and their providers to learn
Read More
Tempus, Leidos Biomedical Research Inc. Launch Effort to Enhance The Cancer Genome Atlas
Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale announced today that it was selected by Leidos Biomedical Research Inc. (Leidos Biomed) to abstract and structure follow-up clinical data for The Cancer Genome Atlas (TCGA) Project for submission to the National Cancer Institute’s Genomic Data Commons (GDC).The Cancer Genome Atlas (TCGA) Project BackgroundThere are 230 distinct investigators that contributed
Read More